Newsroom

LAS VEGAS--(BUSINESS WIRE)--GMO Internet Group sends elite white-hat hackers to DEF CON 34 CTF (Las Vegas, Aug 6–9), chasing a 4th Cloud Village title and first Finals win....

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE KEY INFORMATION Name of person dealing (Note 1)   Fund(s) for whom Sand Grove Capital Management LLP is the Investment Manager Company dealt in   Irish Continental Group Plc Class of relevant security to which the dealings being disclosed relate (Note 2)   €0.065 ordinary s...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mu...

LONDON--(BUSINESS WIRE)--    FORM 8.3 IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION Name of person dealing (Note 1)   Fund(s) for whom Sand Grove Capital Management LLP is the Investment Manager Company dealt in   Permanent TSB Group Holdings plc Class of relevant security to which the dealings being disclosed relate (Note 2)   €0.01 o...

NEW YORK--(BUSINESS WIRE)--KBRA is providing an update on Series 2024-1 and Series 2025-1 (collectively, the Notes) from ExteNet Issuer, LLC (the Issuer), the issuer of a communications infrastructure securitization. According to a recent notice posted by Wilmington Trust, N.A (the Indenture Trustee), the following events of default have occurred: The Issuer failed to pay accrued interest due on the Notes on the July 27, 2026 payment date. Liens granted under the transaction documents with resp...

ROTKREUZ, Suisse--(BUSINESS WIRE)--Polpharma Biologics International AG annonce aujourd’hui que la Food and Drug Administration (FDA) américaine et l’Agence européenne des médicaments (EMA) ont accepté d’examiner respectivement la demande d’autorisation de mise sur le marché de produits biologiques (BLA) et la demande d’autorisation de mise sur le marché (MAA) pour le PB016, un candidat biosimilaire du vedolizumab destiné à remplacer le produit de référence d’Entyvio®* de Takeda (vedolizumab),...

ROTKREUZ, Svizzera--(BUSINESS WIRE)--Polpharma Biologics International AG oggi ha reso noto che la Food and Drug Administration (FDA) degli Stati Uniti e l'Agenzia europea per i medicinali (EMA) hanno accettato la richiesta di revisione relativa rispettivamente alla domanda di licenza per farmaci biologici (BLA) e alla domanda di autorizzazione alla commercializzazione (MAA) per PB016, un candidato biosimilare di vedolizumab rispetto a Entyvio®* (vedolizumab), il prodotto di riferimento di Take...

ROTKREUZ, Schweiz--(BUSINESS WIRE)--Die Polpharma Biologics International AG gibt heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) und die Europäische Arzneimittelagentur (EMA) den Antrag auf Zulassung eines Biologikums (Biologics License Application, BLA) bzw. den Antrag auf Marktzulassung (Marketing Authorisation Application, MAA) für PB016 zur Prüfung angenommen haben. Dabei handelt es sich um einen geplanten Vedolizumab-Biosimilar-Kandidaten für Takeda's Referenzp...

ROTKREUZ, Zwitserland--(BUSINESS WIRE)--Polpharma Biologics International AG maakte vandaag bekend dat de Amerikaanse FDA (U.S. Food & Drug Administration) en de EMA (European Medicines Agency) respectievelijk de BLA (Biologics License Application) en de MAA (Marketing Authorisation Application) ter beoordeling hebben geaccepteerd voor PB016, een voorgesteld vedolizumab biosimilair kandidaatgeneesmiddel voor Takeda’s referentieproduct Entyvio®* (vedolizumab) gevriesdroogde flacon voor IV-to...

ROTKREUZ, Suiza--(BUSINESS WIRE)--Polpharma Biologics International AG anuncia hoy que la U. S. Food and Drug Administration (FDA) y la Agencia Europea de Medicamentos (EMA) han admitido a trámite la solicitud de licencia de productos biológicos (BLA) y la solicitud de autorización de comercialización (MAA), respectivamente, para el PB016, un candidato a biosimilar de vedolizumab propuesto como sustituto del producto de referencia de Takeda, Entyvio®* (vedolizumab), en vial liofilizado para adm...